For this study, researchers analyzed medical records from more than 2 million people taking diabetes medications, including over 215,000 who took GLP-1 medications, from October 2017 through December 2023 via a database maintained by the U.S
But in the beginning of last year, we, we said, no, it has to be for a diabetes prescription. -Senior Human Resources Leader, large services organization The use of GLP-1 agonists was higher than expected for many large employers including for over half (59%) of employers over 5,000 workers Since then, many larger employers covering GLP-1 agonists for weight loss reported higher than expected use of the medications and significant impacts on their prescription spending
Sofwave is also a good option for routine maintenance
Here is how to get the most value from your investment
The FDA may take extra time to evaluate the glucagon-related safety signals, particularly the heart rate increase (up to 6.7 bpm above baseline) and dysesthesia (Nature Medicine, 2024)
However, not all individuals experience the same degree of benefit
